Trials / Completed
CompletedNCT00421915
Study Evaluating Etanercept Treatment of Patients With Ankylosing Spondylitis
Multicenter, Double-Blind, Parallel, Placebo-Controlled, Randomised Phase 3 Study of Etanercept in the Treatment of Patients With Ankylosing Spondylitis: 12-Week Final Data
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 84 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to compare the efficacy of etanercept (25 mg, twice weekly) with that of placebo based on the percentage of patients who achieve the Assessment in Ankylosing Spondylitis (ASAS) response criteria (ASAS 20%) at week 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enbrel (etanercept) |
Timeline
- Start date
- 2002-03-01
- Completion
- 2002-08-01
- First posted
- 2007-01-15
- Last updated
- 2007-01-15
Source: ClinicalTrials.gov record NCT00421915. Inclusion in this directory is not an endorsement.